Pharmaceutical News

RSS

Lower rate of reintubation observed in infants receiving SURFAXIN

Discovery Laboratories, Inc. today announced the presentation of a new pharmacoeconomic analysis demonstrating that the lower rate of reintubation previously reported in infants treated with SURFAXIN, when compared with infants treated with Curosurf® and Survanta®, the current global market leading surfactants, also resulted in a potential hospital cost savings of $160,000 to $252,000 per 100 infants.

2 May 2012

Dixie announces new hemp-based Cannabidiol products without THC

Dixie Elixirs and Edibles, Colorado's premier Tetrahydrocannabinol or THC-infused products company, today announced a new line of products which will break entirely new ground for the company in the category of non-THC-infused product development.

2 May 2012

SMC rules abiraterone as too expensive for routine prostate cancer treatment

Cancer Research UK is extremely disappointed that the advanced prostate cancer drug, abiraterone, has been ruled too expensive for routine use by the Scottish Medicines Consortium (SMC).

2 May 2012

Painkillers create quandary for physicians

News outlets report on the hazards -- both in the ER and in maternity wards -- being brought about by painkiller use and abuse.

2 May 2012

Two MSU researchers invent protein purifier for pharma companies

Two Michigan State University researchers have invented a protein purifier that could help pharmaceutical companies save time and money.

2 May 2012

FDA approves Protalix, Pfizer’s ELELYSO for treatment of type 1 Gaucher disease

Pfizer Inc. and Protalix BioTherapeutics, Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.

2 May 2012

Combination of new prostate cancer drugs can extend life for men

Combing two new prostate cancer drugs could increase the number of men who respond to treatment and the length of time they benefit, research led by The Institute of Cancer Research (ICR) has shown.

2 May 2012

Endocrine Society and its Hormone Health Network release ‘Menopause Map’

Women going through menopause now have a first-of-its-kind interactive guide to help them better understand their menu of treatment options, including whether hormone therapy may be right for them. The Endocrine Society and its Hormone Health Network today released the "Menopause Map," an online tool to help women and their doctors discuss which hormonal and non-hormonal treatment options would be most effective and safe to relieve the sometimes debilitating symptoms of menopause.

2 May 2012

Beta-carotene-derived molecules have opposite effect in the body

New research suggests that there could be health hazards associated with consuming excessive amounts of beta-carotene.

2 May 2012

Non-toxic green tea shampoo to treat dandruff

Dandruff sufferers now have a non-toxic product to treat the condition, says a researcher at Georgia Health Sciences University.

2 May 2012

Human study suggests biological basis for individual differences in behavior

Whether someone is a "go-getter" or a "slacker" may depend on individual differences in the brain chemical dopamine, according to new research in the May 2 issue of The Journal of Neuroscience. The findings suggest that dopamine affects cost-benefit analyses.

2 May 2012

Idera to present data from IMO-8400 preclinical studies on SLE, psoriasis at AAI meeting

Idera Pharmaceuticals, Inc. today announced that it will be presenting data from preclinical studies of its Toll-like receptor (TLR) inhibitor, IMO-8400, in models of systemic lupus erythematosus (SLE) and psoriasis, which suggest that IMO-8400 may be useful for the treatment of both indications.

2 May 2012

NIH study indicates safety of anti-HIV drug tenofovir during pregnancy

Infants born to women who used the anti-HIV drug tenofovir as part of an anti-HIV drug regimen during pregnancy do not weigh less at birth and are not of shorter length than infants born to women who used anti-HIV drug regimens that do not include tenofovir during pregnancy, according to findings from a National Institutes of Health network study.

2 May 2012

Ciprofloxacin, TMP-SMX no longer safe for outpatient urinary tract infection

In a surveillance study of over 12 million bacteria, investigators at The George Washington University and Providence Hospital found E. coli antimicrobial resistance to ciprofloxacin, the most commonly prescribed antimicrobial for urinary tract infections in the U.S., increased over five-fold from 2000 to 2010.

2 May 2012

High-dose glucocorticoids double risk of bacterial infections in children with JIA

Children with juvenile idiopathic arthritis have higher rates of bacterial infection requiring hospitalization, and use of high-dose steroids significantly increases that risk, according to research from the University of Alabama at Birmingham.

2 May 2012

Anlit Advanced Nutrition Supplements to present new products at Vitafoods Europe 2012

Anlit Advanced Nutrition Supplements, an innovative developer of quality consumer vitamins, minerals and dietary supplements for children, will present new and innovative products at Vitafoods Europe 2012, which will take place May 22-24, 2012 in Geneva, Switzerland.

2 May 2012

Interferon linked with increased risk of depression in HCV patients

There's a high rate of depression among patients with hepatitis C, but a standard treatment for the disease includes a drug, interferon, that can cause depression.

2 May 2012

Pfizer receives FDA approval for Elelyso to treat Type 1 Gaucher disease

The U.S. Food and Drug Administration today approved Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare genetic disorder.

2 May 2012

Antibiotic effective for plague gets FDA nod

Federal regulators – The Food and Drugs Administration (FDA), have approved use of an antibiotic to treat plague, an extremely rare, sometimes-fatal bacterial infection.

30 Apr 2012

Some public health advocates disagree with Indian government's decision to roll out pentavalent vaccines, IPS reports

"Ignoring widespread concern over the safety, efficacy and cost of pentavalent vaccines" -- which provide protection against diphtheria, pertussis, tetanus, hepatitis B and haemophilus influenza type b (Hib) -- "India's central health ministry has, this month, approved inclusion of the prophylactic cocktail in the universal immunization program in seven of its provinces," Inter Press Service reports.

30 Apr 2012